A Cancer Drug For Parkinson’s? New Study Raises Hope, Draws Criticism

(By Jon Hamilton for NPR)

A leukemia drug may have cleared another hurdle as a potential treatment for Parkinson’s disease.

But critics say it’s still not clear whether the drug, nilotinib (brand name Tasigna), is truly safe or effective for this use.

In a study of 75 people with Parkinson’s, nilotinib appeared to improve quality of life and boost the chemical dopamine, a team from Georgetown University Medical Center reported Monday in JAMA Neurology.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.